Thank first Jason, joining call. and our XXXX you, everyone, to conference for results quarter thank you
welcome For back Salarius, those of to Salarius, you of those let with are introduce to a the for who and take moment me you who are company. familiar new
Salarius gene helps the stated biotechnology cancers cells and stage or some potential another caused survive of that in is turn that dysregulation area research of clinical referred off company machinery epigenetics. treatments for cancer expression, by hijack genes way, cancers to incorrectly an emerging a on or as to This grow. way, is the developing
seclidemstat non-cytotoxic prostate, an to regulating different key making LSDX melanomas. candidate, drug Seclidemstat enzyme, the lead cancers, including cancers sarcomas, a is which inhibits of oral the treatment agent other is that Ewing many expression is breast, in role it Our ovaries, classic believed gene and in chemotherapy. colon, and from a play
bone children but a on standard-of-care tissue affecting surgeries. primarily young Ewing devastating and and radiation cancer, treatment, lead adults. rare frequently sarcoma chemotherapy, and Our multi-agent potentially disfiguring often is and/or chemotherapy, adults These a intense including and rely children indication, soft young
reaching patients Ewing's five-year and XX%. face Unfortunately, to many relapse to fail mortality or rates XX% respond
patients to All a be potential treatment respond complications option. experience not standard-of-care treatment. In resulting better do addition, many often from the to need we patients and their these has seclidemstat that long-term believe options, better
as NASDAQ XXXX, is a our treat events publicly a highlighted merger Pharma treatment a these believe company evaluate elevated market. as seclidemstat Now, sarcoma, year other investors, Ewing traded among us and the helped coming resources transformative Salarius Flex necessary cancers. capital and listing potential hard in for visibility off the our and by with to We to access our on
and building beyond. throughout data XXXX trial and value events, we disclosures forward, Looking clinical anticipate multiple potential
X, property Phase escalation our strengthening public protecting review we achieved dose advancement completion intellectual deal, have ongoing offering sarcoma January, Ewing the million trial, including With Since a XXXX. the great of X this Phase quarter and clinical portfolio $XX a background, now first of seclidemstat. let's in the of an our
our Most Directors. of clinical of is XX as Board the recently, industry Bill with experience. Intertek Chief seasoned previously a development Executive and as Salarius of Scientific Officer pharmaceutical than executive Directors recently of new Bill more McVicar Chief Dr. of Pharma, Board President the served years the named as Pharmaceuticals. of Flex He Officer Chairman served and
in addition, Phoenix, his a as checkpoint paper in potential this founding a combining minutes. discuss team of February, Translational published inhibitors. Institute or our and Dr. Sunil at Sharma scientific highlighting Arizona, immunotherapies, with scientists I'll In the the Genomic more few such in seclidemstat cancer TGen
Salarius's I Salarius from these outbreak. I or past aspects detail, a health coronavirus thoughts forefront Before is time, this that address several like first ongoing pandemic, is everyone's that businesses challenging to to COVID-XX-related the like capabilities. manufacturing topic all Coronavirus, our resulting more have I with at has our business. not to review the we is would global am COVID-XX all in or and experienced of and quarter and a immune, circumstances months, crisis accomplishments worked impacted society the trials we that clinical report have COVID-XX unexpected in minimal but disruptions pleased in
hold. Due COVID-XX many to have outbreak, on been clinical trials the placed
enroll prioritized sites solid Fortunately, patients. been in remain to advanced the Ewing active trials Salarius and our continue tumors have within trial sarcoma clinical and
treatment. As to investigating XXXX trials and prioritization needs clinical data unmet the plans of during to medical commitment is continuing true XXXX. believe as and both clinical from the is populations, which indicative patient release trials, our facing such, the disclosed with are I seclidemstat Salarius previously in
initiated business and the and the non-essential to COVID-XX of operations. impact mitigate impact employees and in headquarters, our on Having travel. home Houston for we changes where Relative from possible the we suspended mid-March, to continue actions, daily, in a take policy monitor said corrective to this, will Salarius, work situation
ongoing in so clinical clinical our trial sites, to at personnel in on, moving sites. the us the various research trial COVID-XX advancing to you. and like individuals. by sites, to teamwork, continue say I But manufacturing Thank our are of that on resilience various our allowed thank Before our trial hospitals, and And would the I the the been going clinical organizations much demonstrated commitment our these our clinical these personnel situation. truly the have trials want publicly there's partners, during it's contract all remarkable.
I Now, XXXX the move of would like on first to quarter to operational update.
expression. emerging in gene caused the series mentioned I are an circumstances, cancers, Salarius enzymes As of normal human of is that a enzymes Under body. earlier, address called developing potential the company expression maintaining stage treatments clinical gene proper by dysregulation epigenetic for responsible biotechnology
represent can proprietary incorrectly the to cellular off, of and these which genes than points several therapeutic seclidemstat. turn candidate dysregulated However, normal epigenetic drug body our basis This in supporting when support cause dysregulated, can epigenetic lead enzymes on These intervention cancers. and for they progression development the approach of rather attractive enzymes forms function. become cancer, the
from X, an trials. be currently apart because may the X therapeutic we LSDX may LSDX is in our however, and one Seclidemstat molecule Reversibility distinction important profile offer as clinical two only development. stands reversible Phase being Seclidemstat, real LSDX crowd, bind is in evaluated than a reversible window ongoing provide know enzyme of safety improved Phase is inhibitor. that our of believe therapeutic not the this does wider safety and seclidemstat permanently it to that to inhibitors we benefits,
on functions types. and of focus limited is to The of of in of these inhibitors to protein primarily First tumor protein of also interactions. inhibiting LSD number inhibit a its of LSDX impact not a the to unique enzymatic function LSDX variety seclidemstat generation interactions. enzymatic ability inhibit only LSDX function Seclidemstat LSDX LSDX, inhibit ability a but broader both of may allow range wide the
but earlier, relapsed or disease within patients for seclidemstat. of refractory two conducting mentioned potential as need treatment X/X is I clinical options, Ewing sarcoma, Salarius with trials high-unmet As requiring Phase such new first seclidemstat, a
seclidemstat evaluating The activity prostate, which clinical and second solid colorectal, other agent ovarian, seclidemstat with single where advanced tumors, X/X preclinical has breast, includes Phase demonstrated sarcomas, in in patients studies. trial non-Ewing melanoma, cancers is
A the designed of each the seclidemstat. phase dose MTD, open-label at to MTD begins safety potentially dose establishes trials Once be and the are and initial trial pharmacokinetic larger profile preliminary seclidemstat, additional expansion capture MTD trials data. group treated data recommended provide of expand for tolerated efficacy this Phase X as profile dose Both dose. or or the to escalation at safety patients demonstrate phase maximum a will
As earlier, releases in data to clinical mentioned data from these releasing throughout this I plans trials with Salarius continue into begin year. XXXX, next clinical clinical year and two and
enrolling this that approved of the trial clinical patients the are report overseeing the seven to mg review of at advancement Ewing the are XXXX in daily We year, six the and BID dose. into now trial committee of quarter first the safety cohorts, the dosing sarcoma pleased
dose seen not escalation. have we would to-date that further toxicities pleased prevent dose also are We limiting that
evidence program. drug trial exposure in data Thus activity levels where are plateau pharmacological a we proportional are increasing our with positive plasma levels patients, far, the in pharmacokinetic is noted seclidemstat the no in now levels. or dose of at we news, This levels as from above seeing drug the suggests manner, in pre-clinical
also enrolling track mg clinical dose studies tumor trials, the dose in our fourth each escalation Dose triggering is in on tolerated patients which reach of trial. continues escalation advanced at both and now XXXX, solid trials BID cohorts believes dose. XXX Salarius is daily dosing maximum seven to in the are the of
potential a of to there's possibility sarcoma, this need, and tremendous therapeutic more the address Ewing need offers FDA believe a the that we rapid With review process. seclidemstat unmet
Orphan seclidemstat expedited designation. Disease programs the previously valuable the by asset, as development could receive very voucher, sell monetizable Pediatric Salarius granted $XXX of FDA can designation, a is fact, Rare to the which review. designation, has for feel potentially FDA, we Rare Track an drug We Fast for review Pediatric priority take $XX approved In to million and extremely Drug seclidemstat's and FDA's million. Also, well-positioned means if which qualify advantage to Disease well as and designation
seclidemstat clinical strategy. advanced allowing us the developing tumor The to clinical trial is tumor solid better safety our establish while profile more advanced fully future solid
may cancers epigenetic to effects. has anti-proliferative and/or epigenetic LSDX Now, mutations with immunomodulatory third or inhibition, party increased and other sensitivity demonstrated enzymes in mutations research that complexes, have
These advanced enzymes, identified occur be Many in tumors through in the our that genetic responding treatment. patients enrich these include mutations identify SWI/SNF can and solid methyltransferase already likelihood of seclidemstat complex, screens, believe these XX% tumor can By and which or mutations acetyltransferase using available of these commercially and sensitizing harbor roughly established with the solid screens. therefore of and genetic to increase tumors. in cohort, mutations, expansion we patients we
genetic platforms, is is by targeting tumor screens a exist possible enriching in standard it to commercial are approved and if type the clinic, common already implement of strategies in these and these This testing across Since driven setting. the recent common, for gene represent believe selpercatinib more in could FDA three as opportunity alteration. drug reflected We different same Lilly approach significant all becoming a of Salarius. of types this the approval cancers,
which Further, system. known seclidemstat cancer were exploring a of commonly the patient's cancer inhibitors. attack designed combination estimated $XX global inhibitors, of immune use to own annual the checkpoint as in sales billion, expose cells Checkpoint we have of to are with by type immunotherapy,
However, cancer return these about a who therapies do initial only suffer patients disease. work show of of many in And patients. in the response, XX% an
his Sunil promote cells Organoids the infiltration significant study, are As due effector immune a both organoids. and vitro mutation. checkpoint modulated at effector ineffective specific of are ovarian and carry a in of I Sharma tumor increase types the culture. immune growing to In in tumor. to microenvironment This tumor that ability two is inhibitors cancer, because tumor cells anti-tumor often to within seclidemstat mentioned seclidemstat of infiltration in from published investigating lack cell cell earlier, TGen clumps studies, of data Salarius that into two founder the Dr. immunity T team
forward best to immune we're respond lot in excited turn with year. programs. then excited to ways that which We In seclidemstat our There's tumors, development a cold to inhibitor about is and advance by other person's about be hot a identified immune into to lot potential providing currently and hidden be throughout words, treatment. the checkpoint We the opportunity, can updates researching system believe to from this system into progress may tumors significant a and on a our be seclidemstat the look clinical trials. could
call to will With Chief that, Mark, our quarter Officer, financial go Financial of a first report. review brief who please ahead. to pass the Salarius’s I'd Rosenblum, Mark provide like
